16:04 EDT Stoke Therapeutics (STOK) files $400M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Positive Outlook on Stoke Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial for Dravet Syndrome Treatment
- Stoke Therapeutics Advances Phase 3 Study for Dravet Syndrome Treatment
- Stoke Therapeutics Adopts Key Proposals at Annual Meeting
- Stoke Therapeutics Launches Phase 3 EMPEROR Study
- Promising Outlook for Stoke Therapeutics: Buy Rating Backed by Phase 3 Trial Progress and Strong Financial Position